Table of Content

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Rising Geriatric Population
3.2.2. Surge In The Prevalence Of Rheumatoid Arthritis Disease
3.2.3. Growing Healthcare Expenditure
3.3. Key Restraints
3.3.1. Patent Expirations
3.3.2. Lack Of Regulatory Guidelines For Biosimilars Will Delay Their Availability In Some Regions
3.3.3. Less Expensive Alternatives

4. Key Analytics
4.1. Porter’S Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Etiology Of Rheumatoid Arthritis (Ra)
4.3. Symptoms Of Rheumatoid Arthritis
4.4. Risk Factors Associated With Rheumatoid Arthritis
4.5. Opportunity Matrix
4.6. Vendor Landscape
4.7. Key Investment Insights

5. Market By Type
5.1. Prescription-Based Drugs
5.2. Over-The-Counter Drugs

6. Market By Drug Class
6.1. Disease Modifying Anti-Rheumatic Drugs
6.2. Nonsteroidal Anti-Inflammatory Drugs
6.3. Corticosteroids
6.4. Uric Acid Drugs
6.5. Other Drug Class

7. Geographical Analysis
7.1. Europe
7.1.1. The United Kingdom
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Belgium
7.1.7. Poland
7.1.8. Rest Of Europe

8. Company Profiles
8.1. Abbott Laboratories
8.2. Abbvie Inc
8.3. Amgen Inc
8.4. Becton, Dickinson & Company (Bd)
8.5. Bio-Rad Laboratories Inc
8.6. Bristol-Myers Squibb Company
8.7. Eli Lilly & Company
8.8. Lupin Limited
8.9. F. Hoffmann-La Roche
8.10. Johnson & Johnson
8.11. Merck & Co Inc
8.12. Novartis Ag
8.13. Perkinelmer
8.14. Pfizer Inc
8.15. Ucb



List of Figures


List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Europe Anti-Rheumatics Market, By Type, In 2019
Figure 6: Europe Anti-Rheumatics Market, By Prescription-Based Drugs, 2020-2028 (In $ Million)
Figure 7: Europe Anti-Rheumatics Market, By Over-The-Counter Drugs, 2020-2028 (In $ Million)
Figure 8: Europe Anti-Rheumatics Market, By Drug Class, In 2019
Figure 9: Europe Anti-Rheumatics Market, By Disease Modifying Anti-Rheumatic Drugs, 2020-2028 (In $ Million)
Figure 10: Europe Anti-Rheumatics Market, By Nonsteroidal Anti-Inflammatory Drugs, 2020-2028 (In $ Million)
Figure 11: Europe Anti-Rheumatics Market, By Corticosteroids, 2020-2028 (In $ Million)
Figure 12: Europe Anti-Rheumatics Market, By Uric Acid Drugs, 2020-2028 (In $ Million)
Figure 13: Europe Anti-Rheumatics Market, By Other Drug Class, 2020-2028 (In $ Million)
Figure 14: Europe Anti-Rheumatics Market, Country Outlook, 2019 & 2028 (In %)
Figure 15: The United Kingdom Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 16: France Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 17: Germany Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 18: Italy Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 19: Russia Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 20: Belgium Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 21: Poland Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 22: Rest Of Europe Anti-Rheumatics Market, 2020-2028 (In $ Million)


List of Tables


TABLE 1: MARKET SNAPSHOT - ANTI-RHEUMATICS
TABLE 2: COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
TABLE 3: RISK FACTORS FOR RHEUMATOID ARTHRITIS
TABLE 4: EUROPE ANTI-RHEUMATICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: EUROPE ANTI-RHEUMATICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: EUROPE PRESCRIPTION-BASED DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: EUROPE PRESCRIPTION-BASED DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: EUROPE OVER-THE-COUNTER DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: EUROPE OVER-THE-COUNTER DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: EUROPE ANTI-RHEUMATICS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: EUROPE ANTI-RHEUMATICS MARKET, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 12: EUROPE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: EUROPE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 15: EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 16: EUROPE CORTICOSTEROIDS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: EUROPE CORTICOSTEROIDS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: EUROPE URIC ACID DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 19: EUROPE URIC ACID DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 20: EUROPE OTHER DRUG CLASS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 21: EUROPE OTHER DRUG CLASS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 22: EUROPE ANTI-RHEUMATICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 23: EUROPE ANTI-RHEUMATICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)